{"answer":{"query":"Synjardy XR","resolved_as":"applications","packages":10,"applications":["NDA208658"],"identity":{"application_numbers":["NDA208658"],"marketing_categories":["NDA"],"labelers":[],"dosage_forms":[{"text":"TABLET, EXTENDED RELEASE","untrusted":true}],"marketing_start":{"earliest":"2016-12-10","latest":"2016-12-10","packages_with_a_start_date":10}},"generic_entry":[{"application":"NDA208658","date":"2034-12-11","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"9949998*PED","productNo":"003"},"latest_patent_expiry":"2034-12-11","latest_exclusivity_expiry":"2026-12-20","dated_barriers":104,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":14,"exclusivities_listed":2,"fact_id":"959bd9905c952605d632f1ab"}],"label_history":{"events_total":15,"non_cmc_events":15,"counts_by_class":{"LABELING":11,"EFFICACY":4},"cmc_events":0,"recent_non_cmc_events":[{"application":"NDA208658","submission_no":38,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-08-11","documents":[{"type":"Letter","date":"2026-08-14","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/201281Orig1s043;206111Orig1s050;208026Orig1s034;208658Orig1s038;212614Orig1s032ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-08-18","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208658s038lbl.pdf","untrusted":true}}],"fact_id":"77d091cfb1fc699a8d8439ad"},{"application":"NDA208658","submission_no":34,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-10-24","documents":[{"type":"Label","date":"2025-10-27","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206111s046,208658s034lbl.pdf","untrusted":true}},{"type":"Letter","date":"2025-10-28","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/204629Orig1s063,206111Orig1s046,208658Orig1s034,206073Orig1s044,212614Orig1s029ltr.pdf","untrusted":true}}],"fact_id":"899066f01595ff564a1a697d"},{"application":"NDA208658","submission_no":32,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2025-03-07","documents":[{"type":"Letter","date":"2025-03-11","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/206111Orig1s045,208658Orig1s032ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-03-11","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206111s045,208658s032lbl.pdf","untrusted":true}}],"fact_id":"d870f4dc4f903f3c55970b9c"},{"application":"NDA208658","submission_no":28,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2023-10-30","documents":[{"type":"Label","date":"2023-10-31","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206111s042,208658s028lbl.pdf","untrusted":true}},{"type":"Letter","date":"2023-10-31","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/206073Orig1s036; 206111Orig1s042; 208658Orig1s028; 212614Orig1s020ltr.pdf","untrusted":true}}],"fact_id":"c513cec434af247e9b715fea"},{"application":"NDA208658","submission_no":26,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2023-06-20","documents":[{"type":"Letter","date":"2023-06-21","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/206111Orig1s038,s039;208658Orig1s025,s026ltr.pdf","untrusted":true}},{"type":"Label","date":"2023-06-22","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206111s038s039,208658s025s026lbl.pdf","untrusted":true}}],"fact_id":"9e40b569130fa9950cc52ab7"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":4,"te_code_counts":{"NOT_PROVIDED":4},"marketing_status_counts":{"Prescription":4},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA208658","product_no":"004","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"SYNJARDY XR","untrusted":true},"form":{"text":"TABLET, EXTENDED RELEASE;ORAL","untrusted":true},"strength":{"text":"25MG;1GM","untrusted":true}},{"application":"NDA208658","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"SYNJARDY XR","untrusted":true},"form":{"text":"TABLET, EXTENDED RELEASE;ORAL","untrusted":true},"strength":{"text":"5MG;1GM","untrusted":true}},{"application":"NDA208658","product_no":"002","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"SYNJARDY XR","untrusted":true},"form":{"text":"TABLET, EXTENDED RELEASE;ORAL","untrusted":true},"strength":{"text":"10MG;1GM","untrusted":true}},{"application":"NDA208658","product_no":"003","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"SYNJARDY XR","untrusted":true},"form":{"text":"TABLET, EXTENDED RELEASE;ORAL","untrusted":true},"strength":{"text":"12.5MG;1GM","untrusted":true}}]},"recalls":{"recalls_total":3,"counts_by_class":{"Class II":3},"packages_of_these_applications":10,"most_recent":[{"recall_number":"D-0657-2026","classification":"Class II","status":"Ongoing","report_date":"2026-07-08","recall_initiated":"2026-06-12","recalling_firm":{"text":"Boehringer Ingelheim Pharmaceuticals, Inc.","untrusted":true},"reason":{"text":"CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.","untrusted":true},"packages_named":1,"fact_id":"cf1c0e89022dc11b97a90dc9"},{"recall_number":"D-0458-2021","classification":"Class II","status":"Terminated","report_date":"2021-06-02","recall_initiated":"2021-03-15","recalling_firm":{"text":"Cardinal Health Inc.","untrusted":true},"reason":{"text":"CGMP Deviations: Intermittent exposure to temperature excursion during storage.","untrusted":true},"packages_named":10,"fact_id":"fbc28d3bacf1fbc4331dca3a"},{"recall_number":"D-0459-2021","classification":"Class II","status":"Terminated","report_date":"2021-06-02","recall_initiated":"2021-03-15","recalling_firm":{"text":"Cardinal Health Inc.","untrusted":true},"reason":{"text":"CGMP Deviations: Intermittent exposure to temperature excursion during storage.","untrusted":true},"packages_named":10,"fact_id":"f51c3c442725efe10ea683dd"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"EMPAGLIFLOZIN","untrusted":true},"recruiting_interventional_count":94,"not_yet_recruiting_count":29,"by_phase":{"PHASE1/PHASE2":4,"PHASE3":18,"PHASE1":7,"PHASE4":29,"PHASE2":18,"EARLY_PHASE1":8,"NA":6,"PHASE2/PHASE3":4},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT03424005","title":{"text":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"Hoffmann-La Roche","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2018-03-30","link":{"text":"https://clinicaltrials.gov/study/NCT03424005","untrusted":true}},{"nct_id":"NCT05972564","title":{"text":"The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"Vanderbilt University Medical Center","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2023-09-06","link":{"text":"https://clinicaltrials.gov/study/NCT05972564","untrusted":true}},{"nct_id":"NCT07038356","title":{"text":"Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Christian Schulze","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-04","start_date":"2025-12-08","link":{"text":"https://clinicaltrials.gov/study/NCT07038356","untrusted":true}},{"nct_id":"NCT07845630","title":{"text":"A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body","untrusted":true},"phase":["PHASE1"],"sponsor":{"text":"Boehringer Ingelheim","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-29","start_date":"2026-10-14","link":{"text":"https://clinicaltrials.gov/study/NCT07845630","untrusted":true}},{"nct_id":"NCT06249932","title":{"text":"Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"National Taiwan University Hospital","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-28","start_date":"2024-03-13","link":{"text":"https://clinicaltrials.gov/study/NCT06249932","untrusted":true}}],"fact_id":"ab0e426b6d1a73f39080ec45"}]},"assistance_and_offers":{"programs_listing_this_drug":[{"name":{"text":"Teva Cares Foundation","untrusted":true},"type":"manufacturer","url":"https://www.tevacares.org/","status":null,"needs_status_check":false,"has_offer":false},{"name":{"text":"Viatris (Mylan) Patient Assistance","untrusted":true},"type":"manufacturer","url":"https://www.viatris.com/en-us/lm/united-states/patient-assistance-program","status":null,"needs_status_check":false,"has_offer":false},{"name":{"text":"Walmart $4 Prescriptions","untrusted":true},"type":"discount","url":"https://www.walmart.com/cp/4-dollar-prescriptions/1078664","status":null,"needs_status_check":false,"has_offer":false},{"name":{"text":"Mark Cuban Cost Plus Drugs","untrusted":true},"type":"discount","url":"https://costplusdrugs.com/","status":null,"needs_status_check":false,"has_offer":false}],"manufacturer_offers":[],"note":"A program that lists a drug has not decided anything about any person: each program decides who qualifies, and a status other than open means it may not take new patients. Offers change and expire; read each offer's source and stated end date. A price figure is what the page states, not a quote."},"spending":{"reported_under":{"generic":{"text":"Empagliflozin/Metformin HCl","untrusted":true},"brand":{"text":"Synjardy XR","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":89479916.55,"claims":106841,"beneficiaries":24248,"average_spending_per_claim_usd":837.50541974,"fact_id":"d682fbb412dbf2ecfc74b5a2"},{"year":2021,"gross_spending_usd":142731071.31,"claims":152660,"beneficiaries":35523,"average_spending_per_claim_usd":934.96050904,"fact_id":"b03170b87d6144f78a4c9ff1"},{"year":2022,"gross_spending_usd":206951664.21,"claims":202183,"beneficiaries":47124,"average_spending_per_claim_usd":1023.5858812,"fact_id":"ab3025d0750b8214ea24c14d"},{"year":2023,"gross_spending_usd":278415268.5,"claims":252620,"beneficiaries":58868,"average_spending_per_claim_usd":1102.1109512,"fact_id":"8ed2aafa450973ea0f560a4f"},{"year":2024,"gross_spending_usd":320732965.54,"claims":310733,"beneficiaries":70976,"average_spending_per_claim_usd":1032.1818588,"fact_id":"3a7f1aaaf2ab7a9fbef0bd5c"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"orphan_designation":{"ingredients":[{"ingredient":{"text":"empagliflozin","untrusted":true},"designation_count":1,"approved_count":0,"recent":[{"designated":"2026-11-02","use":{"text":"treatment of glycogen storage disease type 1b (GSD1b)","untrusted":true},"status":"Designated","sponsor":{"text":"Vitalis Scientia LLC","untrusted":true},"approved":false}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"2bdcac1644e899b98d840283"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"},"medicaid_state_utilization":{"year":2025,"states_with_data":12,"all_states_medicaid_reimbursed_usd":1486482.32,"all_states_medicaid_paid_prescriptions":2216,"top_states":[{"state":"FL","medicaid_paid_prescriptions":624,"medicaid_reimbursed_usd":400321.89,"total_reimbursed_usd":406036.79,"packages":4,"covers":"fee_for_service_only","fact_id":"b8e7630f98e45f1f823dc8f5"},{"state":"MI","medicaid_paid_prescriptions":404,"medicaid_reimbursed_usd":269732.68,"total_reimbursed_usd":269732.68,"packages":2,"covers":"fee_for_service_only","fact_id":"41ebaacb28a42d4442804bcb"},{"state":"NC","medicaid_paid_prescriptions":197,"medicaid_reimbursed_usd":197345.73,"total_reimbursed_usd":213919.94,"packages":2,"covers":"fee_for_service_only","fact_id":"158f70c672cffadd1dd6b8b1"},{"state":"MS","medicaid_paid_prescriptions":276,"medicaid_reimbursed_usd":154364.88,"total_reimbursed_usd":157930.18,"packages":2,"covers":"fee_for_service_only","fact_id":"196b5d06559a51cb368aaeea"},{"state":"MA","medicaid_paid_prescriptions":153,"medicaid_reimbursed_usd":98402.93,"total_reimbursed_usd":98402.93,"packages":2,"covers":"fee_for_service_only","fact_id":"dadfba914d1330b95b495ab3"},{"state":"UT","medicaid_paid_prescriptions":109,"medicaid_reimbursed_usd":93603.46,"total_reimbursed_usd":94149.96,"packages":2,"covers":"fee_for_service_only","fact_id":"8e513211e4a909fd094f1911"},{"state":"CO","medicaid_paid_prescriptions":105,"medicaid_reimbursed_usd":91387.07,"total_reimbursed_usd":91387.07,"packages":1,"covers":"all_record_types","fact_id":"66e89fe2cbea626e0f76bad7"},{"state":"LA","medicaid_paid_prescriptions":90,"medicaid_reimbursed_usd":46087.61,"total_reimbursed_usd":54142.98,"packages":1,"covers":"all_record_types","fact_id":"39b298931659112609ac2aba"},{"state":"VA","medicaid_paid_prescriptions":71,"medicaid_reimbursed_usd":38078.77,"total_reimbursed_usd":38312.02,"packages":1,"covers":"all_record_types","fact_id":"d14cce6fbb1b07b57940ade1"},{"state":"KS","medicaid_paid_prescriptions":70,"medicaid_reimbursed_usd":37732.5,"total_reimbursed_usd":39691.31,"packages":1,"covers":"all_record_types","fact_id":"6467161ff398de7263821dd8"}],"unlabelled_state_code_xx":null,"built_from_facts":20,"facts_fee_for_service_only":14,"older_year_facts_not_used":99,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"1236ea8c0edfa6bfc490092b","field":"ndc.listing","entity":"ndc:00597028073"},{"fact_id":"28b9fe237d2b7209845fcc2f","field":"ndc.listing","entity":"ndc:00597028090"},{"fact_id":"4cdb791130650b1c60858f30","field":"ndc.listing","entity":"ndc:00597029059"},{"fact_id":"959bd9905c952605d632f1ab","field":"drug.generic_entry_earliest","entity":"application:NDA208658"},{"fact_id":"549cb8dbc01891cf8a6b7ef2","field":"drug.patent","entity":"application:NDA208658"},{"fact_id":"59917d544844552778c61292","field":"drug.exclusivity","entity":"application:NDA208658"},{"fact_id":"77d091cfb1fc699a8d8439ad","field":"drug.label_event","entity":"application:NDA208658"},{"fact_id":"899066f01595ff564a1a697d","field":"drug.label_event","entity":"application:NDA208658"},{"fact_id":"d870f4dc4f903f3c55970b9c","field":"drug.label_event","entity":"application:NDA208658"},{"fact_id":"c513cec434af247e9b715fea","field":"drug.label_event","entity":"application:NDA208658"},{"fact_id":"9e40b569130fa9950cc52ab7","field":"drug.label_event","entity":"application:NDA208658"},{"fact_id":"d040bbd14183e056565f5504","field":"drug.marketing_status","entity":"application:NDA208658"},{"fact_id":"cee161e5dd0271f1afc6c1b9","field":"drug.marketing_status","entity":"application:NDA208658"},{"fact_id":"ae1c6e6f3c4c128d6ad148b2","field":"drug.marketing_status","entity":"application:NDA208658"},{"fact_id":"229db3e6f9cc6b375ff958af","field":"drug.marketing_status","entity":"application:NDA208658"},{"fact_id":"cf1c0e89022dc11b97a90dc9","field":"ndc.recall","entity":"ndc:00597030045"},{"fact_id":"fbc28d3bacf1fbc4331dca3a","field":"ndc.recall","entity":"ndc:00597030020"},{"fact_id":"f51c3c442725efe10ea683dd","field":"ndc.recall","entity":"ndc:00597030020"},{"fact_id":"ab0e426b6d1a73f39080ec45","field":"drug.trial_access","entity":"drug:empagliflozin"},{"fact_id":"d682fbb412dbf2ecfc74b5a2","field":"drug.partd_spending","entity":"drug:empagliflozin-metformin-hcl|synjardy-xr"},{"fact_id":"b03170b87d6144f78a4c9ff1","field":"drug.partd_spending","entity":"drug:empagliflozin-metformin-hcl|synjardy-xr"},{"fact_id":"ab3025d0750b8214ea24c14d","field":"drug.partd_spending","entity":"drug:empagliflozin-metformin-hcl|synjardy-xr"},{"fact_id":"8ed2aafa450973ea0f560a4f","field":"drug.partd_spending","entity":"drug:empagliflozin-metformin-hcl|synjardy-xr"},{"fact_id":"3a7f1aaaf2ab7a9fbef0bd5c","field":"drug.partd_spending","entity":"drug:empagliflozin-metformin-hcl|synjardy-xr"},{"fact_id":"2bdcac1644e899b98d840283","field":"drug.orphan_designation","entity":"drug:empagliflozin"},{"fact_id":"b8e7630f98e45f1f823dc8f5","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597029588:FL"},{"fact_id":"41ebaacb28a42d4442804bcb","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597029588:MI"},{"fact_id":"158f70c672cffadd1dd6b8b1","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597030093:NC"},{"fact_id":"196b5d06559a51cb368aaeea","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597030045:MS"},{"fact_id":"dadfba914d1330b95b495ab3","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597029059:MA"},{"fact_id":"8e513211e4a909fd094f1911","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597029588:UT"},{"fact_id":"66e89fe2cbea626e0f76bad7","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597029588:CO"},{"fact_id":"39b298931659112609ac2aba","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597029578:LA"},{"fact_id":"d14cce6fbb1b07b57940ade1","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597029074:VA"},{"fact_id":"6467161ff398de7263821dd8","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597030045:KS"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price","reason":"no NADAC price, negotiated price or federal upper limit for these packages"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}